INOVIQ (ASX:IIQ) has received a $1.018m refund under the Australian Government’s Research & Development Tax Incentive program ...

Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress ...

For our methodology, we used a stock screener and selected healthcare stocks that had an RSI below 30, mid-market cap, and ...